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Introduction {#sec1}
============

Stroke is the leading cause of mortality and disability in the adult population ([@bib19], [@bib20]), and approximately 70% of all strokes are ischemic strokes ([@bib24]). Restoration of blood flow to the brain with thrombolysis or endovascular thrombectomy after ischemic stroke onset is the most effective therapeutic strategy to reduce the infarct region and salvage the cells in the ischemic penumbra ([@bib33]). However, reperfusion itself contributes to cerebral injury and greatly increases the incidence of cerebral edema and hemorrhagic transformation ([@bib4]). Blood deficiency and resupply during ischemia/reperfusion (I/R) disrupts brain energy homeostasis, which inevitably aggravates glutamate excitotoxicity, calcium overload, free radical formation, and inflammation, known as the traditional underlying mechanisms of I/R injury ([@bib28], [@bib45]).

The brain accounts for only 2% of the body weight but consumes 20% of the energy of the whole body ([@bib34]). Thus, slight energy deficiency in the brain causes severe dysfunction. Glycogen is the only endogenous energy reserve for the brain during cerebrovascular obstruction and is steadily and dynamically maintained through the balance between glycogenesis and glycogenolysis ([@bib3]). Glycogen synthase kinase-3 (GSK3) and protein kinase A (PKA) comodulate the activity of glycogen synthase (GS), the rate-limiting enzyme in glycogenesis ([@bib58]). Glycogen phosphorylase (GP), the key enzyme in glycogenolysis, is controlled by the PKA-glycogen phosphorylase kinase (PhK) cascade ([@bib58]). Glycogen is mainly located in astrocytes, but recently, very sensitive assays revealed that it exists in small amounts in neurons with active glycogen metabolism ([@bib16], [@bib47]). Glycogen plays important roles in astrocyte energetics, including pumping Ca^2+^ into the endoplasmic reticulum (ER) controlling the extracellular K^+^ concentration and managing oxidative stress ([@bib12], [@bib13]). In addition, the stored glycogen in astrocytes can be rapidly triggered to generate metabolic support for neighboring neurons by switching astrocytic glycolysis from blood-borne glucose to glycogen, which spares an equivalent amount of blood-borne glucose for neurons ([@bib14]). However, little is known about the alterations in glycogen metabolism that occur during recanalization and their impacts on neurological outcomes after ischemic stroke.

Here, we provide evidence that strongly suggests glycogen accumulation at the onset of reperfusion is associated with the development of I/R injury in stroke patients and animal models. In addition, dysfunction of the PKA-PhK-GP cascade is involved in glycogenolytic reprogramming in astrocytes. Genetic and pharmacological augmentation of glycogen breakdown during recirculation could rescue astrocyte and cocultured neuron survival and improve neurological outcomes after ischemic stroke. In addition, we found that insulin exhibits neuroprotective effects, at least in part by rescuing the PKA-PhK-GP cascade to maintain homeostasis of glycogen metabolism during reperfusion.

Results {#sec2}
=======

Glycogen Accumulates in the Human, Primate, and Rodent Brain during Recanalization after Ischemia {#sec2.1}
-------------------------------------------------------------------------------------------------

Firstly, we conducted studies on brain tissues from 4 stroke patients who received thrombolytic treatment within 6 h after the onset of stroke. The postmortem interval was approximately 30--40 min, and the interval between thrombolysis and death for these patients ranged from 11 h to 14 h ([Table S1](#mmc1){ref-type="supplementary-material"}). A schematic of the penumbra in the ipsilateral hemisphere and the homologous region in the contralateral hemisphere was shown in [Figure 1](#fig1){ref-type="fig"}A (top panel). The levels of glycogen significantly increased in the penumbra compared with the contralateral region after recanalization in stroke patients, as indicated by periodic acid-Schiff (PAS) staining and biochemical assays ([Figure 1](#fig1){ref-type="fig"}A, bottom and right panel). Glycogen accumulation was also observed in monkey and mouse brains at 12 h after reperfusion ([Figure 1](#fig1){ref-type="fig"}A, bottom and right panel), indicating that reperfusion-induced glycogen accumulation is common across species. The oxygen-glucose deprivation/reoxygenation (OGD/R) model was further used to mimic I/R stress *in vitro*. Consistent with the results obtained *in vivo*, extensive glycogen accumulation was observed in cultured astrocytes *in vitro* after OGD/R, as demonstrated by PAS staining and biochemical assays ([Figure 1](#fig1){ref-type="fig"}B). In addition, cellular localization was investigated using electron microscopy, and we observed that a large amount of glycogen was mainly distributed in astrocytes but not neurons at 12 h in the mouse I/R model ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Cerebral Glycogen Is Substantially Increased in Human, Primate, Rodent, and Cultured Astrocytes at the Onset of Reperfusion(A) A representative diagram showing the core infarct and penumbral regions in the ipsilateral hemisphere after I/R onset (top). Glycogen accumulated in the ischemic penumbra of the ipsilateral hemisphere compared with the contralateral hemisphere in humans (n = 4, paired samples ttest), monkeys (n = 6, paired samples ttest, at 12 h after reperfusion), and mice (n = 8, paired samples ttest, at 12 h after reperfusion) after reperfusion, as indicated by PAS staining. The glycogen levels in the ischemic penumbra of the ipsilateral hemisphere and the homologous contralateral hemisphere were quantified with a biochemical assay. The arrows indicate glycogen-positive cells. Scale bars represent 50 μm.(B) Increased glycogen in cultured astrocytes, as revealed by PAS staining and a biochemical assay at 12 h after reoxygenation (n = 8, independent ttest). The arrows indicate glycogen-positive cells. Scale bars represent 100 μm.(C) Excessively elevated glycogen was localized in astrocytes but not neurons at 12 h after reperfusion in the mouse brain, as revealed using electron microscopy. The arrows indicate glycogen granules. Nu represents the nucleus. Cyto represents the cytoplasm. The blue dashed lines represent nuclear membranes, and the red dashed lines represent cell membranes. Scale bars represent 1 μm.The data are presented as the mean ± SEM. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Table S1](#mmc1){ref-type="supplementary-material"} and [Figures S1](#mmc1){ref-type="supplementary-material"} and [S14](#mmc1){ref-type="supplementary-material"}.

Next, dynamic changes in glycogen accumulation were investigated separately using electron microscopy and biochemical assays. Glycogen granule levels began to increase 2 h after reperfusion, peaked at 12 h, and accumulated for at least 72 h in the mouse model of middle cerebral artery occlusion/reperfusion (MCAO/R) ([Figures 2](#fig2){ref-type="fig"}A--2C). Consistent with these *in vivo* data, glycogen levels were substantially elevated in cultured astrocytes after OGD/R ([Figures 2](#fig2){ref-type="fig"}D--2F). The glycogen levels in cultured astrocytes began to increase 6 h after reoxygenation, were at least two-fold higher than the initial levels at 12 h and remained elevated for at least 72 h in the OGD/R model ([Figures 2](#fig2){ref-type="fig"}E and 2F). In addition, we observed that glycolytic capacity was inhibited and ATP production decreased at 12 h after reperfusion in the cultured astrocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 2Glycogen Accumulation Lasts for at Least 72 h after I/R in Rodents and Cultured Astrocytes(A) Representative electron microscopy images of brain glycogen in mice subjected to MCAO/R. The arrows indicate glycogen granules. Scale bars represent 1 μm.(B and C) Quantified glycogen granules (B, n = 6, one-way ANOVA with the Dunnett T3 multiple comparisons test) and glycogen levels (C, n = 6, factorial analysis) in the ischemic penumbra after reperfusion.(D) Representative electron microscopy images of glycogen in cultured astrocytes during reoxygenation. The arrows indicate glycogen granules. Scale bars represent 1 μm.(E and F) Quantified glycogen granules (E, n = 6, one-way ANOVA with the Dunnett T3 multiple comparisons test) and glycogen levels (F, n = 5, one-way ANOVA with the Dunnett T3 multiple comparisons test) in cultured astrocytes after reoxygenation.The data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Dysfunction of Astrocytic GP Is Responsible for the Extensive Glycogen Accumulation Caused by Suppression of PKA/PhK {#sec2.2}
--------------------------------------------------------------------------------------------------------------------

The basal glycogen levels in astrocytes depend on the balance between glycogenesis and glycogenolysis ([@bib9]). We first detected the expression of key enzymes in glycogenesis and glycogenolysis in cultured astrocytes. In addition to GS, glycogen branching enzyme (GBE1) plays a role in cerebral glycogenesis to some extent ([@bib9]). We found that the mRNA and protein levels of GS and GBE1 were relatively stable at different time points during OGD/R stress ([Figures 3](#fig3){ref-type="fig"}A, 3B, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). GP has three isoforms in the brain: PYGB (brain isoform of GP), PYGM (muscle isoform of GP), and PYGL (liver isoform of GP) ([@bib9]), and we found the mRNA proportion of PYGB, PYGM, and PYGL was 91.7%, 6.1%, and 2.2% in cultured astrocytes, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The changes in the protein and mRNA levels of PYGB, PYGM, and PYGL during OGD/R are presented in [Figures 3](#fig3){ref-type="fig"}C--3E and [S2](#mmc1){ref-type="supplementary-material"}D--S2F. Protein level was lowest for PYGB at 12 h, when its mRNA expression was also half of the normal level ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}D). Both the mRNA and protein levels of glycogen debranchingenzyme (AGL), another key enzyme in glycogenolysis, showed no significant changes ([Figures 3](#fig3){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}G). Subsequently, we investigated the activity of GS and GP. The activity of GS was not markedly affected after reoxygenation, as determined by biochemical analysis ([Figure 3](#fig3){ref-type="fig"}G). However, total GP activity was decreased at 12 h after reoxygenation according to a biochemical assay ([Figure 3](#fig3){ref-type="fig"}H).Figure 3Relative mRNA Expressions and *In Vitro* Activities of Enzymes Involved in Glycogen Metabolism Are Selectively Reduced at 12 h after OGD/R in Cultured Astrocytes(A--F) The mRNA levels of GS (A), GBE1 (B), PYGB (C), PYGM (D), PYGL (E), and AGL (F) were determined by quantitative reverse transcription polymerase chain reaction (RT-qPCR) at 12 h after reoxygenation in cultured astrocytes (n = 8, independent t test).(G--L) Quantified GS (G), GP (H), PhK (I), PKA (J), GSK3α (K), and GSK3β (L) activities in astrocytes at 12 h after reoxygenation in cultured astrocytes (n = 8, independent t test).The data are presented as the mean ± SEM. ^∗∗∗^p \< 0.001. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.

The next question is why GP, but not GS, is dysfunctional during I/R. Previous evidence has suggested that the PKA-PhK-GP pathway controls glycogen degradation and that both PKA and GSK3 can inhibit the activity of GS ([@bib58]). Here, we found that the activity of PhK was decreased at 12 h after reoxygenation following OGD ([Figure 3](#fig3){ref-type="fig"}I). The activity of PKA was also reduced during reoxygenation ([Figure 3](#fig3){ref-type="fig"}J). There was no change in the activity of GSK3α, an isoform of GSK3 ([Figure 3](#fig3){ref-type="fig"}K), but the activity of GSK3β was upregulated ([Figure 3](#fig3){ref-type="fig"}L).

Given that cultured astrocytes are unlikely to completely represent the *in vivo* situation, we adopted double-labeled immunofluorescence to specifically quantify the relative expressions of key enzymes in astrocytes in a mouse model of MCAO. First, the fluorescence intensity of S100β, used as an astrocytic marker in immunofluorescence, remained stable at 12 h after reperfusion ([Figure S3](#mmc1){ref-type="supplementary-material"}). Second, we found that the expression of GS, GBE1, PYGM, PYGL, and AGL was relatively stable at 12 h after reperfusion in astrocytes (marked by S100β, [Figures 4](#fig4){ref-type="fig"}A, 4B, and 4D--4F). However, a 53.5% reduction in PYGB expression was observed at 12 h after MCAO/R ([Figure 4](#fig4){ref-type="fig"}C). Previous studies suggested that phosphorylated GS and N-terminal serine phosphorylated GSK-3β were the inactivated forms and that phosphorylation is the activated form for GP and PKA ([@bib48], [@bib50], [@bib58]). We found that the level of phosphorylated GS in astrocytes was not changed after reperfusion ([Figure 4](#fig4){ref-type="fig"}G). We also synthesized a new antibody against phosphorylated PYGB ([Figure S4](#mmc1){ref-type="supplementary-material"}) and found that the level of phosphorylated PYGB in astrocytes dropped to 5.1% of that in the sham group at 12 h after MCAO/R ([Figure 4](#fig4){ref-type="fig"}H). In addition, we found that the level of phosphorylated PKA was significantly decreased at 12 h after reperfusion ([Figure 4](#fig4){ref-type="fig"}I) and that there was a decrease in the expression of inactivated phosphorylated GSK3β at 12 h after recanalization ([Figure 4](#fig4){ref-type="fig"}J).Figure 4Protein Levels of Enzymes Involved in Glycogen Metabolism Are Selectively Reduced after Reperfusion in a Mouse Stroke Model(A--F) Left panels: coronal immunofluorescence images of frontal cortex area 1 in the ischemic penumbra after staining with an antibody against S100β and antibodies against GS (A), GBE1 (B), PYGB (C), PYGM (D), PYGL (E), and AGL (F). Right panels: quantification of relative fluorescence intensity of GS (A), GBE1 (B), PYGB (C), PYGM (D), PYGL (E), and AGL (F) in astrocytes of the ischemic penumbra at 12 h after reperfusion (n = 8, independent t test). Astrocytes were marked with S100β. The relative fluorescence intensity of the target protein was calculated as the percentage of fluorescence intensity in the colocalization area (denoted as S100β and target protein) divided by the fluorescence intensity in the S100β^+^ area. Scale bars represent 50 μm.(G--J) Left panels: coronal immunofluorescence images of frontal cortex area 1 in the ischemic penumbra after staining with an antibody against S100β and antibodies against phosphorylated GS (p-GS, G), phosphorylated PYGB (p-PYGB, H), phosphorylated PKA (p-PKA, I) and phosphorylated GSK3β (p-GSK3β, J). Right panels: quantification of relative fluorescence intensity of p-GS (G), p-PYGB (H), p-PKA (I), and p-GSK3β (J) in astrocytes of the ischemic penumbra at 12 h after reperfusion (n = 8, independent ttest). Astrocytes were marked with S100β. Scale bars represent 50 μm.The data are presented as the mean ± SEM. ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}, [S4](#mmc1){ref-type="supplementary-material"}, and [S13](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

Augmenting Astrocytic PYGB Increases the Survival of Both Astrocytes and Cocultured Neurons and Improves Neurological Outcomes after I/R {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------------------

To determine the potential clinical significance of glycogen disorders in cerebrovascular disease, we first used lentiviruses to construct PYGB overexpression (Ve-Pygb) and CRISPR/Cas9-mediated PYGB knockdown (Sg-Pygb) models *in vitro* ([Figure S5](#mmc1){ref-type="supplementary-material"}). We found that GP mRNA expression and *in vitro* activity were partially restored at 12 h after OGD/R in PYGB-overexpressing astrocytes, whereas PYGB knockdown reduced GP mRNA level and *in vitro* activity ([Figures 5](#fig5){ref-type="fig"}A and 5B). Elevated glycogen was decreased in the PYGB overexpression model but was further increased with PYGB knockdown after OGD/R ([Figure 5](#fig5){ref-type="fig"}C). Next, the cell viability of astrocytes increased with PYGB overexpression and decreased with PYGB knockdown under OGD/R insult ([Figure 5](#fig5){ref-type="fig"}D). The proportion of apoptotic astrocytes also decreased with PYGB overexpression ([Figure 5](#fig5){ref-type="fig"}E). In addition, we found that a pharmacological PKA agonist (8-Br-cAMP, 10 μM) significantly activated GP and suppressed GS at 12 h after OGD/R ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Glycogen levels also decreased and the viability of astrocytes increased upon treatment with 8-Br-cAMP ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D).Figure 5Enhancement of Astrocytic PYGB Improves the Survival of Cultured Astrocytes and Cocultured Neurons During OGD/R(A) Quantified PYGB mRNA levels in PYGB-overexpressing (Ve-Pygb) and PYGB-knockdown (Sg-Pygb) cultured astrocytes at 12 h after reoxygenation (n = 8, one-way ANOVA with the Dunnett T3 multiple comparisons test). Sg represents astrocytes infected with scrambled sgRNA lentiviruses. Ve represents astrocytes infected with blank vector lentiviruses.(B) Quantified GP activity in PYGB overexpressing and knockdown cultured astrocytes at 12 h after reoxygenation (n = 8, one-way ANOVA with the Dunnett T3 multiple comparisons test).(C) Glycogen concentrations in PYGB overexpressing and knockdown cultured astrocytes during OGD/R stress (n = 3, factorial analysis).(D) The relative cell viability of cultured astrocytes was determined by a Cell Counting Kit-8 (CCK-8) assay at 24 h after the onset of reoxygenation (n = 9, one-way ANOVA with the LSD multiple comparisons test). The control condition means that the astrocytes received only culture medium changes (containing glucose) at the same timepoints as the OGD/R group but no OGD stress.(E) The numbers of apoptotic cultured astrocytes at 24 h after OGD/R were analyzed by TUNEL staining (n = 7, independent t test). The top panel represents the total cells stained by DAPI, and the bottom panel represents the apoptotic astrocytes stained by TUNEL. Scale bars represent 100 μm.(F) Diagram of the astrocyte-neuron coculture system.(G) Viability of neurons at 24 h after reoxygenation in the coculture system (n = 8, one-way ANOVA with the LSD multiple comparisons test). The control condition means that the cocultured neurons received only culture medium changes (containing glucose) at the same timepoints as the OGD/R group but no OGD stress.(H) Apoptosis analysis of neurons at 24 h after reoxygenation in the coculture system (n = 7, independent t test). Scale bars represent 100 μm.(I) LDH release in the coculture medium (n = 8, one-way ANOVA with the Dunnett T3 multiple comparisons test).The data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}, [S6](#mmc1){ref-type="supplementary-material"}, and [S15](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.

Considering the metabolic coupling between astrocytes and neurons, a coculture system was used that allowed the two cell types to share diffusible metabolic substrates but remain divided by a physical filter ([Figure 5](#fig5){ref-type="fig"}F). After genetic enhancement of astrocytic PYGB, the viability of neurons was significantly increased, whereas the number of apoptotic neurons was markedly decreased during reoxygenation ([Figures 5](#fig5){ref-type="fig"}G and 5H). In contrast, neuronal viability decreased when astrocytic PYGB was silenced ([Figure 5](#fig5){ref-type="fig"}G). The observed decreases in lactate dehydrogenase (LDH) in the coculture medium further revealed that the overall survival of neurons and astrocytes was promoted by the augmentation of astrocytic PYGB during OGD/R ([Figure 5](#fig5){ref-type="fig"}I).

To evaluate whether genetic enhancement of astrocyticglycogenolysis alleviates brain injury, a knock-in mouse model with astrocyte-specific PYGB overexpression (KI-Pygb) was constructed, and the KI-Pygb mice showed no differences in appearance but had increases in the expressions of PYGB and phosphorylated PYGB compared with those of their wild-type (WT) littermate controls ([Figure S7](#mmc1){ref-type="supplementary-material"}). Histological and neurobehavioral analyses were performed in the acute and subacute phases ([@bib40]) after MCAO/R, according to the timeline shown in [Figure 6](#fig6){ref-type="fig"}A. Immunofluorescence analysis revealed that the expression of PYGB and phosphorylated PYGB in astrocytes was partially restored at 12 h after reperfusion in transgenic mice compared with WT mice ([Figures 6](#fig6){ref-type="fig"}B and 6C). Accordingly, brain glycogen accumulation was significantly attenuated at 12 h after reperfusion in KI-Pygb mice compared with WT mice ([Figure 6](#fig6){ref-type="fig"}D). The infarct volumes were notably decreased in KI-Pygb mice during the acute phase after reperfusion ([Figure 6](#fig6){ref-type="fig"}E). In addition, a corner test was performed to assess sensorimotor dysfunction ([@bib56]), and the number of right turns was clearly decreased in the KI-Pygb mice compared with the WT group after reperfusion ([Figure 6](#fig6){ref-type="fig"}F). A grid-walking test was also performed to detect the degree of motor impairment ([@bib5]), and PYGB enhancement led to significant increases in total steps and decreases in the foot fault ratio after restoration of circulation ([Video S1](#mmc2){ref-type="supplementary-material"} and [Figure 6](#fig6){ref-type="fig"}G). The infarct volumes were markedly decreased in the KI-Pygb mice during the subacute phase after MCAO/R, as revealed by Nissl staining ([Figure 6](#fig6){ref-type="fig"}H).Figure 6Enhancement of Astrocytic PYGB Ameliorates Ischemic Outcomes during MCAO/R(A) Left panel: schematic of the corner test and grid-walking test patterns. Right panel: timeline of biochemical, neurobehavioral, and neuropathological analyses after MCAO/R treatment.(B) Left panel: coronal immunofluorescence images of frontal cortex area 1 in the ischemic penumbra after staining with an antibody against S100β and an antibody against PYGB. Right panel: quantification of relative fluorescence intensity of PYGB in astrocyte-specific PYGB knock-in (KI-Pygb) mice and WT mice at 12 h after reperfusion (n = 8, independent t test). Astrocytes were marked with S100β. The relative fluorescence intensity of PYGB was calculated as the percentage of fluorescence intensity in the colocalization area (denoted as S100β and PYGB) divided by the fluorescence intensity in the S100β^+^ area. Scale bars represent 50 μm.(C) Left panel: coronal immunofluorescence images of frontal cortex area 1 in the ischemic penumbra after staining with an antibody against S100β and an antibody against phosphorylated PYGB (p-PYGB). Right panel: quantification of relative fluorescence intensity of p-PYGB in KI-Pygb mice and WT mice at 12 h after reperfusion (n = 8, independent t test). Astrocytes were marked with S100β. Scale bars represent 50 μm.(D) Cerebral glycogen levels in the ischemic penumbra at 12 h after MCAO/R (n = 6, independent t test).(E) Left panel: representative brain slice images of triphenyltetrazolium chloride (TTC) staining at 24 h after MCAO/R. Right panel: the quantified infarct volumes of TTC staining (WT: n = 8; KI-Pygb: n = 7, independent ttest). Scale bars represent 1 mm.(F) A corner test was performed to analyze the numbers of right turns in 10 trials before (Pre) and after reperfusion in the mouse model of MCAO (WT: n = 8; KI-Pygb: n = 7, repeated measures analysis).(G) A grid-walking test was performed to assess the total steps (left panel) and foot fault ratios (right panel) before (Pre) and after reperfusion in the mouse model of MCAO (WT: n = 8; KI-Pygb: n = 7, repeated measures analysis).(H) Nissl staining was used to assess infarct volumes at day 14 after MCAO/R (WT: n = 10; KI-Pygb: n = 9, independent ttest). Scale bar represents 2 mm.The data are presented as the mean ± SEM. ^∗∗^p \< 0.01. ^∗∗∗^p \< 0.001. See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Video S1](#mmc2){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

Video S1. A Typical Video Clip of WT and KI-Pygb Mice Performing the Grid-Walking Test on Day 14 after MCAO/R, Related to Figure 6

Insulin Mediates Neuroprotection by Rebalancing Glycogen Metabolism via Activation of PKA/PhK and Suppression of GSK-3β {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------

Insulin is a proteohormone that is critical for the maintenance of hepatic glycogen homeostasis ([@bib37]) and mediates cardioprotective effects on I/R in heart ([@bib7]). Here, we found that the increased glycogen levels gradually returned to normal levels after treatment with increasing concentrations of insulin (IS) during reoxygenation ([Figure 7](#fig7){ref-type="fig"}A). In addition, a significant increase in GP activity, but no effect on GS activity, was found in cultured astrocytes at 12 h after OGD/R with insulin (1 μM) treatment ([Figures 7](#fig7){ref-type="fig"}B, 7C, and [S8](#mmc1){ref-type="supplementary-material"}). Unexpectedly, insulin was observed to enhance GS activity rather than GP activity in normal cultured astrocytes ([Figure S9](#mmc1){ref-type="supplementary-material"}). This discrepancy prompted us to uncover the upstream alterations in glycogen metabolism. We found that both PhK and PKA were upregulated at 12 h after reoxygenation after insulin treatment ([Figures 7](#fig7){ref-type="fig"}D and 7E). The activity of GSK3β was decreased with insulin treatment, whereas the activity of GSK3α was unchanged ([Figures 7](#fig7){ref-type="fig"}F and 7G). Subsequently, similar to the above data *in vitro*, intracerebroventricular insulin (10 μM) treatment increased the levels of phosphorylated PYGB, PKA, and GSK3β, with no effects on phosphorylated GS in mouse brains at 12 h after blood recirculation ([Figures 7](#fig7){ref-type="fig"}H--7K). And the fluorescence intensity of S100β remained stable with intracerebroventricular insulin treatment for 12 h ([Figure S10](#mmc1){ref-type="supplementary-material"}).Figure 7Insulin Activates GP, PhK, and PKA Activities and Suppresses GSK3β Activity in Cultured Astrocytes and Increases Their Relative Fluorescence in Rodents after I/R(A) Glycogen concentrations in cultured astrocytes treated with different doses of insulin after reoxygenation (n = 4, factorial analysis). Insulin was added to the medium immediately after reoxygenation. VEH represents the vehicle group, and IS represents the insulin group.(B--G) The activities of GS (B), GP (C), PhK (D), PKA (E), GSK3α (F), and GSK3β (G) were quantified at 12 h after reoxygenation in cultured astrocytes treated with insulin (1 μM) (n = 8, independent t test).(H--K) Left panels: coronal immunofluorescence images of frontal cortex area 1 in the ischemic penumbra after staining with an antibody against S100β and antibodies against phosphorylated GS (p-GS, H), phosphorylated PYGB (p-PYGB, I), phosphorylated PKA (p-PKA, J), and phosphorylated GSK3β (p-GSK3β, K). Right panels: quantification of relative fluorescence intensity of p-GS (H), p-PYGB (I), p-PKA (J), and p-GSK3β (K) in the ischemic penumbra at 12 h after reperfusion (n = 8, independent t test). Astrocytes were marked with S100β. Insulin (10 μM) was injected into the lateral ventricle immediately after reperfusion to achieve a final concentration of approximately 1 μM in the cerebrospinal fluid. The relative fluorescence intensity of the target protein was calculated as the percentage of fluorescence intensity in the colocalization area (denoted as S100β and target protein) divided by the fluorescence intensity in the S100β^+^ area. Scale bars represent 50 μm.The data are presented as the mean ± SEM. ^∗∗∗^p \< 0.001. See also [Figures S8--S10](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

We next examined the role of astrocyticglycogenolysis in insulin-mediated neuroprotection using Sg-Pygb models *in vitro*. The insulin-induced decrease in glycogen was attenuated in GP knockdown astrocytes during OGD/R ([Figure 8](#fig8){ref-type="fig"}A). Astrocyte survival appeared to be increased with insulin treatment but decreased with concomitant PYGB knockdown lentivirus treatment during reoxygenation, as determined by cell viability and apoptosis rate analyses ([Figures 8](#fig8){ref-type="fig"}B and 8C). Cocultured neuron survival was notably improved by insulin treatment during OGD/R, and this improvement could be blocked by coculture with GP knockdown astrocytes ([Figures 8](#fig8){ref-type="fig"}D and 8E). LDH release into the coculture medium also decreased with insulin treatment and increased when astrocytic PYGB was inhibited during reoxygenation ([Figure 8](#fig8){ref-type="fig"}F).Figure 8Insulin Decreases Astrocyte and Neuron Death and Protects the Brain Damage during I/R Injury by Enhancing Astrocytic GP Activity(A) Glycogen level in cultured astrocytes at 12 h after OGD/R (n = 8, one-way ANOVA with the LSD multiple comparisons test). Insulin (1 μM) was added to the medium immediately after reoxygenation. VEH represents the vehicle group, and IS represents the insulin group. Sg represents astrocytes infected with scrambled sgRNA lentiviruses. Sg-Pygb represents GP-knockdown astrocytes.(B) Relative cell viability of the cultured astrocytes at 24 h after reoxygenation (n = 8, one-way ANOVA with the LSD multiple comparisons test). The control condition means that the astrocytes received culture medium changes (containing glucose) without OGD/R stress.(C) The numbers of apoptotic cultured astrocytes were analyzed by TUNEL staining at 24 h after reoxygenation (n = 7, one-way ANOVA with the LSD multiple comparisons test). Scale bars represent 100 μm.(D) Viability of neurons treated at 24 h after reoxygenation in the astrocyte-neuron coculture system (n = 8, one-way ANOVA with the LSD multiple comparisons test). The control condition means that the cocultured neurons received culture medium changes (containing glucose) without OGD/R stress.(E) The numbers of apoptotic neurons in coculture were analyzed by TUNEL staining at 24 h after reoxygenation (n = 7, one-way ANOVA with the LSD multiple comparisons test). Scale bars represent 100 μm.(F) LDH release in the coculture medium was analyzed (n = 8, one-way ANOVA with the Dunnett T3 multiple comparisons test).(G) Glycogen levels in the ischemic penumbra at 12 h after MCAO/R in mice (n = 7, one-way ANOVA with the LSD multiple comparisons test). Insulin (10 μM) was injected into the lateral ventricle immediately after reperfusion to achieve a final concentration of approximately 1 μM in the cerebrospinal fluid. Sh represents mice infected with scrambled shRNA AAVs. Sh-Pygb represents PYGB knockdown mice.(H) The infarct volumes at 24 h after MCAO/R in mice were analyzed by TTC staining (n = 9, one-way ANOVA with the LSD multiple comparisons test). Scale bars represent 1 mm.(I) A corner test was performed to analyze the numbers of right turns in 10 trials before (Pre) and after reperfusion in the mouse model of MCAO (n = 7, repeated measures analysis).(J) A grid-walking test was performed to assess the total steps (left panel) and foot fault ratios (right panel) before (Pre) and after reperfusion in the mouse model of MCAO (n = 7, repeated measures analysis).(K) Nissl staining was used to assess infarct volumes at day 14 after MCAO/R in mice (n = 7, one-way ANOVA with the LSD multiple comparisons test). Scale bar represents 2 mm.The data are presented as the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figures S11](#mmc1){ref-type="supplementary-material"} and [S12](#mmc1){ref-type="supplementary-material"}.

To conditionally suppress astrocytic PYGB expression *in vivo*, an adeno-associated virus (AAV) containing the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter ([@bib8]) and an exogenous short hairpin RNA (shRNA) targeting the *pgyb* gene was constructed (Sh-Pygb). Exogenous shRNA, which was marked by FLAG, was predominantly localized in astrocytes, which were marked by GFAP ([Figure S11](#mmc1){ref-type="supplementary-material"}A). The expression of astrocytic PYGB and phosphorylated PYGB was clearly downregulated in the PYGB knockdown mice ([Figures S11](#mmc1){ref-type="supplementary-material"}B--S11D). The accumulated glycogen in the mouse brain was also diminished with insulin treatment after reperfusion, and the decreases in glycogen were suppressed in mice with *pygb*-modified astrocytes ([Figure 8](#fig8){ref-type="fig"}G). Furthermore, the infarct volumes were decreased after insulin administration, and astrocytic PYGB inhibition blocked this effect at 24 h after MCAO/R ([Figure 8](#fig8){ref-type="fig"}H). Consistent with the above acute-phase data, neurobehavioral and neuropathological impairments were revealed to be significantly alleviated with insulin treatment in the corner test ([Figure 8](#fig8){ref-type="fig"}I) and grid-walking test ([Figure 8](#fig8){ref-type="fig"}J) and by Nissl staining ([Figure 8](#fig8){ref-type="fig"}K) during the subacute phase of recirculation; these effects were markedly blocked when astrocyticglycogenolysis was suppressed. In addition, intraventricular injection of insulin did not affect blood glucose after MCAO/R operation ([Figure S12](#mmc1){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

The present study reveals that the accumulation of glycogen is strongly associated with the development of I/R injury in mice subjected to transient cerebral ischemia and cultured astrocytes treated with OGD. Our findings provide the evidence that glycogen accumulation is common across species following transient cerebral ischemia. We found that PYGB, the brain isoform of GP in glycogenolysis, plays a substantial role in glycogen-accumulation-associated neuropathy. The PKA-PhK-GP cascade participates in the reprogramming of glycogenolysis during recanalization after ischemic stroke and reoxygenation after OGD.

In this study, we examined cerebral glycogen levels after stroke in humans and nonhuman primates and found that glycogen was excessively accumulated in the ischemic penumbra of humans and nonhuman primates after cerebral I/R, which is consistent with findings from previous observations in rodents ([@bib18], [@bib23], [@bib25], [@bib26]). To determine the time window for glycogen accumulation after cerebral I/R, brain glycogen levels were continuously detected until 72 h after reperfusion in a focal ischemia rodent model, and we showed that astrocytic glycogen accumulated at 6 h and peaked at 12 h after cerebral reperfusion. Notably, postmortem tissue handling caused glycogen loss in the contralateral hemisphere of stroke patients in this study, because glycogen levels in [Figure 1](#fig1){ref-type="fig"}A were reduced to approximately 13% compared with those reported in a previous study ([@bib27]). Postmortem loss of glycogen could also be expected in the monkey and mouse brains and cultured astrocytes due to the lag time between decapitation and freezing or cell lysis (See [Transparent Methods](#mmc1){ref-type="supplementary-material"}).

Considering the pivotal role of glycogen in maintaining cerebral physiological function, elucidation of the underlying mechanism of reperfusion-induced glycogen accumulation is necessary. Limited evidence suggests that GSK3beta activity is upregulated during I/R stress ([@bib46]). Theoretically, GSK3β inhibits GS activity through phosphorylation, and inactivation of GS could decrease the levels of glycogen during I/R ([@bib44]). However, where is the excessive glycogen in astrocytes derived from after recirculation? The PKA-PhK-GP pathway has been revealed to determine glycogen degradation in the liver, and PKA can suppress GS activity as well ([@bib58]). These clues prompted us to investigate the alterations of these key enzymes in glycogen metabolism. We found that the astrocytic PKA-PhK-GP cascade was significantly inactivated during reperfusion. The activity of GS remained at normal levels due to the neutralizing effects of PKA suppression and GSK3β activation. Interestingly, inequality of changes in mRNA level and protein level related to enzyme activity was found in this study. For instance, [Figure 4](#fig4){ref-type="fig"}C showed a 53.5% reduction in PYGB expression, whereas the level of phosphorylated PYGB in astrocytes dropped to 5.1% at 12 h after MCAO/R in [Figure 4](#fig4){ref-type="fig"}H. Also, in [Figure 7](#fig7){ref-type="fig"}C, the *in vitro* activity of GP increased after insulin-treated, whereas its protein level was still decreased at 12 h after OGD/R ([Figure S8](#mmc1){ref-type="supplementary-material"}C). In addition, we observed that the expression of PYGB was preferentially affected in mice suffered from MCAO/R and in cultured astrocytes subjected to OGD/R compared with that of PYGM and PYGL. We are not sure whether only PYGB activity was also decreased during reperfusion because the activities of PYGM and PYGL were not detected in this study. No evidence suggests that the PKA-PhK pathway regulates only PYGB not PYGM or PYGL activity. Therefore, we speculate that PYGB is vulnerable to I/R mainly because it accounts for a large proportion of GP mRNA isoforms in cultured astrocytes (91.7%).

Our findings seem to be inconsistent with the existing idea that glycogen storage caused by pharmacological inhibition of glycogenolysis can prevent energy crisis and alleviate brain damage. Constant perfusion of the glycogen breakdown inhibitor, ingliforib, to increase glycogen levels 30 min before myocardial ischemia shows a cardioprotective effect, because glycogen is rapidly degraded to glucose-1-phosphate to provide additional energy ([@bib49]). Some GP inhibitors, such as CP-316819 and maslinic acid, have also been used to elevate the levels of brain glycogen before brain ischemia ([@bib22], [@bib53]). Release of prestored glycogen has been viewed as a promising therapeutic strategy to rapidly supply energy under ischemia and alleviate brain damage ([@bib53]). However, pharmacological treatments targeting glycogenolysis should be carefully used. Our results showed that reprogramming of GP and impairment of glycogen breakdown, instead of glycogen deficit, occurred during the reperfusion phase. Previous studies also revealed that the elevation of glycogen levels during recirculation is prolonged in proportion to the duration of ischemia ([@bib29], [@bib38], [@bib39]). We strongly suspect that sustained pharmacological action of these GP inhibitors during the reperfusion stage will lead to an aggravated ischemic outcome. Therefore, the timing of pharmacological intervention is particularly important, and short-acting GP antagonists and GP agonists may need be administered separately before ischemia and after reperfusion, respectively, according to the patient\'s condition.

In this study, we revealed that the mobilization of glycogenolysis in astrocytes contributes to the survival of neighboring neurons after reperfusion. This phenomenon is interesting, but the underlying mechanism might be complicated. Previous studies have provided clues about how degraded glycogen attenuates neuronal damage. First, extra glycogen could fuel Na^+^/K^+^-ATPase to enhance K^+^ uptake in astrocytes and improve neuronal excitation recovery ([@bib52]). The activation of Na^+^/K^+^-ATPase also accelerates excitatory glutamate uptake by stimulating the excitatory amino acid transporter and attenuates glutamate excitotoxicity to neurons ([@bib51], [@bib54]). In addition, glycogen might provide energy for loading Ca^2+^ into the ER and relieve the neuronal damage caused by calcium overload ([@bib32]). Finally, increased glucose-6-phosphate resulting from glycogen feedback inhibits hexokinase, thereby reducing astrocyte consumption of blood-borne glucose and sparing glucose in neurons ([@bib14]). Notably, we observed a 43% reduction in glycolytic capacity during OGD/R stress in this study. However, this did not confirm that degraded glycogen could not be used as a fuel for astrocytes because the capacity of most enzymes is suggested to greatly exceed the flux through the metabolic step ([@bib30]). In a word, we speculate that in the context of ischemia, compromised astrocytes can boost their energy reserves by reprogramming astrocyte-neuron interactions after reperfusion. Further study should focus on these pathways to elucidate the underlying metabolic profiles during glycogen mobilization and to determine their implications for clinical stroke therapy.

During the past several decades, the glucose, insulin, and potassium (GIK) metabolic cocktail has been widely used in the clinic for cardioprotection after myocardial infarction. Growing evidence has revealed that insulin, but not glucose or potassium, plays an important role in the protective effects of GIK against I/R injury ([@bib55]). The underlying mechanism of insulin-mediated neuroprotection has been reported to primarily depend on maintenance of calcium homeostasis, inhibition of inflammation, and downregulation of free radical release in heart ([@bib7]). In addition, insulin can stimulate erythropoietin production ([@bib35]), regulate gliotransmission ([@bib11]), and modulate glucose metabolism ([@bib17]) in astrocytes and stimulate glucose utilization ([@bib1], [@bib43]) in neurons, which may also contribute to recovery after I/R. However, we cannot ignore the fact that insulin is an important regulator of glycogen homeostasis in the body and that its glycogenic target in the context of neuroprotection is far from completely understood. Recent studies revealed that insulin suppresses the activity of GSK3β through activation of the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB) pathway upon I/R stress ([@bib7], [@bib36]). Notably, the levels of brain glycogen decreased with insulin treatment during reperfusion in this study, which seems to contradict the finding that insulin promotes glycogen synthesis by inhibiting GSK3β. Here, we found that insulin could also activate the PKA-PhK-GP pathway and that the neuroprotective effects of insulin could be attenuated by PYGB knockdown, which may account for the contribution of insulin-mediated recovery during the acute and subacute phases after stroke. Therefore, insulin in the brain is more likely to act as a coordinator to maintain glycogen metabolic homeostasis rather than to simply accelerate glycogen synthesis when the level of glycogen has already substantially increased during reperfusion.

Collectively, our findings provide evidence that glycogen accumulation occurs in humans and monkeys following transient ischemia and that reprogramming of glycogenolysis leads to astrocytic glycogen accumulation and brain damage. Enhancing glycogenolytic metabolism during the acute stage of reperfusion may protect the brain from I/R injury. These results also support the notion that the activated PKA-PhK-GP cascade underlies insulin-mediated neuroprotection. Thus, glycogenolysis is a potential intervention target for ischemic stroke, but the precise application of targeting strategies should be carefully considered according to the timing of ischemia.

Limitations of the Study {#sec3.1}
------------------------

One limitation is the possibility that I/R insult has effects on malin or laforin, leading to an abnormal structure of glycogen that then accumulates, as in Lafora disease ([@bib15], [@bib21]), which is independent of deficits in GP and its upstream signaling pathways. In our study, we did not detect the activities of laforin and malin in I/R injury. However, we observed that cerebral reperfusion did not induce changes in the expression of laforin and malin in astrocytes ([Figure S13](#mmc1){ref-type="supplementary-material"}). In addition, a previous study revealed that accumulated glycogen is not restricted to astrocytes but can be detected in neurons in Lafora disease ([@bib2]). As shown in [Figure 1](#fig1){ref-type="fig"}C, no accumulated glycogen granules were found in neurons using electron microscopy in the mouse MCAO/R model. Therefore, it is conceivable that glycogen accumulation was not due to laforin or malin dysfunction during cerebral reperfusion disorders, but this remains to be further tested.

Another limitation is the existence of some methodological weaknesses in this study. First, the lag time of dissection to obtain the penumbra tissue in sample handling during the glycogen quantitative assay caused glycogen loss. Previous studies suggest that at least 50% of glycogen degrades in 30 s after decapitation in adult mice ([@bib31]), and our glycogen levels in the mouse cortex are approximately half of those reported previously ([@bib42]). In addition, all methods to harvest tissue and cells for glycogen assays had a lag time before freezing or lysis during which glycogenolysis might have occurred, particularly in the control samples where GP activity was not affected. This would cause underestimation of glycogen concentration in the control samples and overestimation of relative postischemic concentration. Therefore, microwave fixation of mouse brain tissue, which preserves glycogen much better than decapitation ([@bib42]), should be adopted for glycogen quantitative assays in future studies. Secondly, double-labeled immunofluorescence has some disadvantages for the quantification of enzyme activity *in vivo*. The S100β is mainly in astrocytic soma that reports only about 15% of the cell volume ([@bib10]), and most of the volume that also contains about half of the glycogen ([@bib42]) and presumably related enzymes is actually in the small processes that were not analyzed in the present study. In addition, the expression of phosphorylated enzyme does not equal the actual activity of the enzyme, and the relationship between fluorescence intensity and expression of the target protein is not linear ([@bib6], [@bib41]), which illustrates that immunofluorescence is imprecise and only a semiquantitative method to evaluate enzyme activities *in vivo*. More precise methods might be developed to quantify astrocyte-specific enzyme activity *in vivo*. Thirdly, hyperglycemia is known to worsen stroke outcome ([@bib57]) and use of 25 mM glucose in the cultures might exaggerate damage caused by OGD in this study. Normal glucose medium (5.5 mM glucose) should be used in the future related studies.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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